PBIO — Pressure BioSciences Share Price
0.000.00%
Last trade - 00:00- $4.42m
- $26.80m
- $1.98m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.37 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -681.29% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1.81 | 1.22 | 2 | 1.73 | 1.98 | n/a | n/a | -4.25% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Pressure BioSciences, Inc. is engaged in the development and sale of enabling, high pressure technology-based instruments, consumables, and services for the life sciences and other industries worldwide. Its products/services are based on three high-pressure platforms: Ultra Shear Technology (UST), BaroFold Technology (BaroFold), and Pressure Cycling Technology (PCT). The UST platform allows for the creation of stable nanoemulsions of otherwise immiscible oil-based active components in water. It also allows for the preparation of higher quality, homogenized, extended shelf-life or room temperature-stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. PCT utilizes alternating cycles of pressure to control biomolecular interactions (such as cell lysis and biomolecule extraction) safely and reproducibly. The BaroFold platform provides valuable contract services and GMP manufacturing equipment to the biopharmaceutical industry.
Directors
- Jeffery Peterson NEC (65)
- Richard Schumacher PRE (70)
- Edmund Ting SVP (67)
- Alexander Lazarev CSO (56)
- Vito Mangiardi IND (72)
- Kevin Pollack IND (50)
- Michael Urdea IND (68)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- August 15th, 1978
- Public Since
- October 31st, 1996
- No. of Shareholders
- 215
- No. of Employees
- 15
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 34,710,509
- Address
- 480 Neponset St., CANTON, 02021
- Web
- https://www.pressurebiosciences.com/
- Phone
- +1 5082301828
- Contact
- Richard Schumacher
- Auditors
- Malone Bailey, LLP
Upcoming Events for PBIO
Q3 2024 Pressure Biosciences Inc Earnings Release
Similar to PBIO
Aamaxan Transport
Pink Sheets on Nasdaq
ACCUSTEM SCIENCES
Pink Sheets on Nasdaq
Acutus Medical
Pink Sheets on Nasdaq
ADM Tronics Unlimited
Pink Sheets on Nasdaq
Advanced Biomedical Technologies
Pink Sheets on Nasdaq
FAQ
What is the Pressure BioSciences share price?
As of Today at 22:45 UTC, shares in Pressure BioSciences are trading at $0.13. This share price information is delayed by 15 minutes.
How has the Pressure BioSciences share price performed this year?
Shares in Pressure BioSciences last closed at $0.13 and the price had moved by -82.92% over the past 365 days. In terms of relative price strength the Pressure BioSciences share price has underperformed the S&P500 Index by -85.66% over the past year.
What are the analyst and broker recommendations for Pressure BioSciences?
There is no consensus recommendation for this security.
What is the Pressure BioSciences dividend yield?
Pressure BioSciences does not currently pay a dividend.
Does Pressure BioSciences pay a dividend?
Pressure BioSciences does not currently pay a dividend.
When does Pressure BioSciences next pay dividends?
Pressure BioSciences does not currently pay a dividend.
How do I buy Pressure BioSciences shares?
To buy shares in Pressure BioSciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Pressure BioSciences?
As of the previous close price of $0.13, shares in Pressure BioSciences had a market capitalisation of $4.68m.
Where are Pressure BioSciences shares listed?
Here are the trading details for Pressure BioSciences:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: PBIO
What kind of share is Pressure BioSciences?
Based on an overall assessment of its quality, value and momentum Pressure BioSciences is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Pressure BioSciences share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Pressure BioSciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Pressure BioSciences. Over the past six months, its share price has underperformed the S&P500 Index by -65.5%.
As of the last closing price of $0.13, shares in Pressure BioSciences were trading -54.98% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Pressure BioSciences PE Ratio?
The Pressure BioSciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.13.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Pressure BioSciences?
Pressure BioSciences' management team is headed by:
- Jeffery Peterson - NEC
- Richard Schumacher - PRE
- Edmund Ting - SVP
- Alexander Lazarev - CSO
- Vito Mangiardi - IND
- Kevin Pollack - IND
- Michael Urdea - IND